Publication: Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
Issued Date
2018-05-01
Resource Type
ISSN
16626567
Other identifier(s)
2-s2.0-85052621957
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Case Reports in Dermatology. Vol.10, No.2 (2018), 198-202
Suggested Citation
Phatcharawat Chirasuthat, Pamela Chayavichitsilp Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma. Case Reports in Dermatology. Vol.10, No.2 (2018), 198-202. doi:10.1159/000492172 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46680
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
Other Contributor(s)
Abstract
© 2018 The Author(s). Atezolizumab is a humanized anti-PD-L1 immune checkpoint antibody that is currently used in many kinds of advanced carcinoma including metastatic non-small cell lung cancer. The cutaneous side effect profile reported only 20% of the patients which had only mild maculopapular rash that required no treatment. There is no case report of anti-PD-L1 antibody-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) eruptions. To the best of our knowledge, there is no case report of atezolizumab-induced SJS or SJS/TEN induced by anti-PD-L1 immune checkpoint antibodies. We believe that our report will be useful to dermatologists who are consultants in the inpatient settings, as atezolizumab is an anti-neoplastic agent that has a potential to be used in multiple malignancies.